CN101534843A - 泊洛沙姆用于预防和/或治疗心力衰竭的用途 - Google Patents

泊洛沙姆用于预防和/或治疗心力衰竭的用途 Download PDF

Info

Publication number
CN101534843A
CN101534843A CNA2007800367818A CN200780036781A CN101534843A CN 101534843 A CN101534843 A CN 101534843A CN A2007800367818 A CNA2007800367818 A CN A2007800367818A CN 200780036781 A CN200780036781 A CN 200780036781A CN 101534843 A CN101534843 A CN 101534843A
Authority
CN
China
Prior art keywords
poloxamer
heart failure
patient
heart
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800367818A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·E·马克哈姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phrixus Pharmaceuticals Inc
Original Assignee
Phrixus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phrixus Pharmaceuticals Inc filed Critical Phrixus Pharmaceuticals Inc
Publication of CN101534843A publication Critical patent/CN101534843A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800367818A 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途 Pending CN101534843A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83472806P 2006-08-01 2006-08-01
US60/834,728 2006-08-01

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN2013100791323A Division CN103222984A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2011100477182A Division CN102218077A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013101207279A Division CN103271935A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Publications (1)

Publication Number Publication Date
CN101534843A true CN101534843A (zh) 2009-09-16

Family

ID=38805633

Family Applications (4)

Application Number Title Priority Date Filing Date
CNA2007800367818A Pending CN101534843A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013100791323A Pending CN103222984A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2011100477182A Pending CN102218077A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013101207279A Pending CN103271935A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN2013100791323A Pending CN103222984A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2011100477182A Pending CN102218077A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013101207279A Pending CN103271935A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Country Status (7)

Country Link
US (1) US9155758B2 (enExample)
EP (1) EP2046348B1 (enExample)
JP (2) JP5537152B2 (enExample)
CN (4) CN101534843A (enExample)
AU (1) AU2007281531B2 (enExample)
CA (1) CA2659909A1 (enExample)
WO (1) WO2008016640A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5537152B2 (ja) 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ， インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2011156389A2 (en) * 2010-06-07 2011-12-15 The Regents Of The University Of California The islet amyloid polypeptide toxic oligomer is a biomarker of heart or kidney failure in type-2 diabetes mellitus
US20160235781A1 (en) * 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
TWI688392B (zh) 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
WO2016007542A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20230190676A1 (en) * 2020-07-09 2023-06-22 Musc Foundation For Research Development Methods of protecting cells from insults
CN111973623B (zh) * 2020-08-06 2022-04-05 温州医科大学 心力衰竭靶向治疗的速释制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0576612B1 (en) 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
WO2000021543A1 (en) 1998-10-09 2000-04-20 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US7341552B2 (en) 2002-03-15 2008-03-11 The University Of Texas System Board Of Regents Gene sets for glioma classification
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
WO2006037031A2 (en) 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
CA2599219C (en) 2005-02-25 2011-09-20 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
PT1861080E (pt) 2005-03-21 2010-06-17 Santhera Pharmaceuticals Ch Derivado de quinona 2,3-dimetoxi-5-metil-6-(10- hidroxidecil)-1,4-benzoquinona para o tratamento de distrofias musculares
DK1978947T3 (da) 2006-02-03 2014-11-03 Nicox Science Ireland Nitrooxyderivater til anvendelse ved behandling af muskeldystrofier
JP5537152B2 (ja) 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ， インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009078978A2 (en) 2007-12-14 2009-06-25 Phrixus Pharmaceuticals, Inc. Compositions containing polyglycidol-based polymers and uses thereof
EP2719389B1 (en) 2007-12-17 2016-07-06 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2011066201A2 (en) 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Methods and systems for treating and preventing cardiac injury in dystrophic subjects

Also Published As

Publication number Publication date
AU2007281531B2 (en) 2013-07-04
EP2046348A2 (en) 2009-04-15
AU2007281531A1 (en) 2008-02-07
EP2046348B1 (en) 2015-07-22
JP2009545595A (ja) 2009-12-24
JP5537152B2 (ja) 2014-07-02
CN102218077A (zh) 2011-10-19
CA2659909A1 (en) 2008-02-07
US20090246162A1 (en) 2009-10-01
WO2008016640A2 (en) 2008-02-07
WO2008016640A3 (en) 2009-02-05
CN103271935A (zh) 2013-09-04
US9155758B2 (en) 2015-10-13
JP2013253103A (ja) 2013-12-19
CN103222984A (zh) 2013-07-31

Similar Documents

Publication Publication Date Title
CN102218077A (zh) 泊洛沙姆用于预防和/或治疗心力衰竭的用途
Ezekowitz et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
RU2518745C2 (ru) Доставка октреотида из сухих лекарственных форм
US20090176772A1 (en) Method of reversing left ventricular remodeling
CN102209529A (zh) 将药物组合物递送至有需要的患者的方法
CN110167538B (zh) 用于治疗心血管疾病的方法
US11197869B2 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
AU2010214636A1 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
Kasama et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril
EP4511040A1 (en) Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock
US9757411B2 (en) Poloxamer therapy for heart failure
US20060019954A1 (en) Method for reducing the likelihood of the occurrence of cardiac arrhythmias
CN116531363A (zh) 甲基麦冬黄酮a在制备治疗心血管疾病药物中的应用
EA052076B1 (ru) Комбинация зиботентана и дапаглифлозина для лечения хронического заболевания почек
WO2009055421A1 (en) Chimeric c3-like rho antagonist cardiac therapeutic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090916